Total Payments
$265,728
2024 Payments
$13,940
Companies
26
Transactions
701
Medicare Patients
9,264
Medicare Billing
$1.2M
Payment Breakdown by Category
Other$218,918 (82.4%)
Travel$23,490 (8.8%)
Food & Beverage$13,264 (5.0%)
Consulting$9,979 (3.8%)
Education$77.51 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $218,493 | 105 | 82.2% |
| Travel and Lodging | $23,490 | 134 | 8.8% |
| Food and Beverage | $13,264 | 440 | 5.0% |
| Consulting Fee | $9,979 | 13 | 3.8% |
| Honoraria | $425.00 | 1 | 0.2% |
| Education | $77.51 | 8 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $124,604 | 203 | $0 (2024) |
| Amgen Inc. | $51,167 | 96 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $47,453 | 104 | $0 (2024) |
| Novo Nordisk Inc | $16,180 | 42 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $13,207 | 49 | $0 (2021) |
| EKOS Corporation | $3,758 | 3 | $0 (2017) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,420 | 17 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $968.05 | 40 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $834.53 | 51 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $790.15 | 21 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,940 | 44 | Novo Nordisk Inc ($12,972) |
| 2023 | $11,245 | 58 | PFIZER INC. ($8,789) |
| 2022 | $15,650 | 59 | PFIZER INC. ($12,986) |
| 2021 | $14,425 | 75 | AstraZeneca Pharmaceuticals LP ($3,776) |
| 2020 | $21,060 | 46 | PFIZER INC. ($8,541) |
| 2019 | $89,614 | 130 | PFIZER INC. ($55,490) |
| 2018 | $54,674 | 149 | Amgen Inc. ($23,389) |
| 2017 | $45,119 | 140 | E.R. Squibb & Sons, L.L.C. ($18,000) |
All Payment Transactions
701 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $21.16 | General |
| Category: Genetic Disease | ||||||
| 12/17/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.21 | General |
| Category: Cardiology | ||||||
| 12/12/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $25.56 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $29.82 | General |
| Category: Cardiovascular | ||||||
| 11/19/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: Diabetes | ||||||
| 11/08/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,938.00 | General |
| Category: Diabetes | ||||||
| 11/05/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $33.28 | General |
| Category: Cardiovascular | ||||||
| 11/05/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $1.82 | General |
| Category: Cardiovascular | ||||||
| 10/30/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: Obesity | ||||||
| 10/29/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $24.34 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/28/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,938.00 | General |
| Category: Diabetes | ||||||
| 10/27/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $124.46 | General |
| Category: Cardio-renal | ||||||
| 10/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $30.73 | General |
| Category: Cardio-renal | ||||||
| 10/18/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,938.00 | General |
| Category: Diabetes | ||||||
| 10/17/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $22.19 | General |
| Category: Cardiovascular | ||||||
| 10/15/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $36.68 | General |
| Category: Cardiovascular | ||||||
| 10/09/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,938.00 | General |
| Category: Diabetes | ||||||
| 09/27/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $14.04 | General |
| Category: Cardiovascular | ||||||
| 09/25/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,550.00 | General |
| 09/24/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $28.03 | General |
| Category: Cardiology | ||||||
| 09/11/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $25.75 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/05/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $39.79 | General |
| Category: Cardiovascular | ||||||
| 07/18/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $17.15 | General |
| Category: Cardiovascular | ||||||
| 07/17/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/26/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: Cardio-renal | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 2,653 | 3,301 | $1.2M | $333,454 |
| 2022 | 17 | 2,421 | 3,021 | $1.1M | $308,475 |
| 2021 | 16 | 2,426 | 3,005 | $1.1M | $329,982 |
| 2020 | 14 | 1,764 | 2,205 | $795,260 | $229,087 |
Total Patients
9,264
Total Services
11,532
Medicare Billing
$1.2M
Procedure Codes
84
All Medicare Procedures & Services
84 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 454 | 454 | $261,050 | $81,756 | 31.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 330 | 558 | $251,100 | $81,219 | 32.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 283 | 418 | $129,700 | $41,823 | 32.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 185 | 188 | $103,400 | $27,242 | 26.3% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 114 | 119 | $71,400 | $24,776 | 34.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 109 | 120 | $72,000 | $21,425 | 29.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 128 | 128 | $73,600 | $19,359 | 26.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 329 | 568 | $42,600 | $7,121 | 16.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 107 | 109 | $27,250 | $6,291 | 23.1% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Office | 2023 | 113 | 118 | $19,470 | $5,438 | 27.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 27 | 30 | $12,750 | $3,166 | 24.8% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Office | 2023 | 113 | 118 | $29,500 | $2,583 | 8.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 28 | 31 | $11,625 | $2,376 | 20.4% |
| 93350 | Ultrasound of heart during rest, exercise and/or drug-induced stress with report | Facility | 2023 | 34 | 34 | $6,800 | $1,962 | 28.9% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 22 | 22 | $2,375 | $1,391 | 58.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 17 | $4,250 | $1,139 | 26.8% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 55 | 56 | $7,675 | $998.48 | 13.0% |
| 93288 | Evaluation of single, dual, multiple lead or leadless pacemaker system | Office | 2023 | 13 | 16 | $1,200 | $779.22 | 64.9% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 33 | 34 | $2,550 | $740.86 | 29.1% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 55 | 56 | $8,875 | $657.44 | 7.4% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Facility | 2023 | 34 | 34 | $5,610 | $507.62 | 9.0% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Facility | 2023 | 16 | 17 | $1,275 | $370.43 | 29.1% |
| 93246 | Heart rhythm recording of continous external ekg over 8-15 days | Office | 2023 | 21 | 22 | $1,650 | $244.90 | 14.8% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 34 | 34 | $8,500 | $87.72 | 1.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 323 | 544 | $244,800 | $78,524 | 32.1% |
About Dr. Charles Dow, M.D
Dr. Charles Dow, M.D is a Cardiovascular Disease healthcare provider based in Roxbury Crossing, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023043874.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Dow, M.D has received a total of $265,728 in payments from pharmaceutical and medical device companies, with $13,940 received in 2024. These payments were reported across 701 transactions from 26 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($218,493).
As a Medicare-enrolled provider, Dow has provided services to 9,264 Medicare beneficiaries, totaling 11,532 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 84 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Roxbury Crossing, MA
- Active Since 07/11/2006
- Last Updated 04/10/2009
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1023043874
Products in Payments
- ELIQUIS (Drug) $119,896
- Repatha (Biological) $50,779
- VYNDAQEL (Drug) $47,934
- Ozempic (Drug) $14,568
- FARXIGA (Drug) $13,027
- EKOSONIC (Device) $3,758
- PRADAXA (Drug) $3,350
- XARELTO (Drug) $968.05
- ENTRESTO (Drug) $696.10
- CAMZYOS (Drug) $455.38
- Adempas (Drug) $427.34
- Product in Development (Device) $425.00
- Corlanor (Drug) $388.28
- INJECTAFER (Drug) $383.06
- Kerendia (Drug) $362.81
- ONPATTRO (Drug) $274.61
- VERQUVO (Drug) $213.87
- BRILINTA (Drug) $202.58
- NEXLETOL (Drug) $165.30
- LEQVIO (Drug) $138.43
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.